Circio Holding ASA (OSE: CRNA), a biotechnology firm focused on circular RNA and immunotherapy medicines, has dosed the first patient in the phase 2 trial sponsored by Georgetown University.

The study evaluates the mutant RAS cancer vaccine TG01 in combination with daratumumab (Janssen) and nivolumab (BMS) for patients with RAS-mutated pancreatic cancer (PDAC) and anti-PD1 resistant non-small cell lung cancer (NSCLC). RAS mutations, prevalent in over 90% of PDAC and 30% of NSCLC patients, pose a significant challenge with limited targeted treatment options.

The phase 2 trial, enrolling 54 KRAS-mutated patients, aims to address this unmet medical need in advanced PDAC and anti-PD1 resistant NSCLC.